Search

AB-1002 (Asklepios and Bayer) Gene Therapy for Heart Failure

AB-1002 (Bayer AG) is an investigational one-time gene therapy administered via intracoronary artery infusion to reduce symptoms of advanced nonischemic heart failure.

Complete this form to request the full report